RPL8 and melanoma: The two recurrent start-gain mutations occurred exclusively in melanoma samples: RPL8; ENST00000262584:c.-94G>A (7 patients, 4.6%) and DCAF7; ENST00000310827:c.-207G>A (3 patients, 2.0%).